Hodgkin Lymphoma - Pipeline Review, H2 2014

Hodgkin Lymphoma - Pipeline Review, H2 2014

Jul 2014 Global Markets Direct Lymphoma214 Pages Price :
$ 2000
Hodgkin Lymphoma - Pipeline Review, H2 2014

Summary

Global Markets Directs, Hodgkin Lymphoma - Pipeline Review, H2 2014, provides an overview of the Hodgkin Lymphomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Hodgkin Lymphoma Overview 11
Therapeutics Development 12
Pipeline Products for Hodgkin Lymphoma - Overview 12
Pipeline Products for Hodgkin Lymphoma - Comparative Analysis 13
Hodgkin Lymphoma - Therapeutics under Development by Companies 14
Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 17
Hodgkin Lymphoma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Hodgkin Lymphoma - Products under Development by Companies 23
Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 24
Hodgkin Lymphoma - Companies Involved in Therapeutics Development 25
Bristol-Myers Squibb Company 25
Johnson & Johnson 26
Seattle Genetics, Inc. 27
Merck & Co., Inc. 28
Gamida Cell Ltd. 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
Ono Pharmaceutical Co., Ltd. 32
Sigma-Tau S.p.A. 33
Incyte Corporation 34
4SC AG 35
Dynavax Technologies Corporation 36
Spectrum Pharmaceuticals, Inc. 37
Affimed Therapeutics AG 38
Actinium Pharmaceuticals, Inc. 39
Philogen S.p.A. 40
Constellation Pharmaceuticals, Inc. 41
Stemline Therapeutics, Inc. 42
Syndax Pharmaceuticals, Inc. 43
Acetylon Pharmaceuticals, Inc. 44
Rhizen Pharmaceuticals SA 45
Immune Pharmaceuticals, Inc. 46
Hodgkin Lymphoma - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 52
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 61
procarbazine hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
panobinostat - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
StemEx - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
brentuximab vedotin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
entinostat - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ixazomib citrate - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MK-2206 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
brentuximab vedotin - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
resminostat - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
ruxolitinib phosphate - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
AFM-13 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
nivolumab - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
radretumab - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Iomab-B - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
ricolinostat - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Ferritarg - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
JNJ-40346527 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Minor Histocompatibility Antigen - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
pevonedistat hydrochloride - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
MDX-1401 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
vinorelbine tartrate liposomal - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
SD-101 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Cell Therapy for Oncology and Infectious Disease - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
NSC-678515 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Cell Therapy to Inhibit CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Cell Therapy 3 for Oncology - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
LMP-400 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
LMP-776 - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
pembrolizumab - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
TGR-1202 - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Cell Therapy for Oncology - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
INCB-047986 - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
CPI-0610 - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
Cell Therapy for Oncology and Infectious Diseases - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Monoclonal Antibody to Inhibit CD47 for Metastatic Solid Tumors - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
SL-101 - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Ferritizumab - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
Hodgkin Lymphoma - Recent Pipeline Updates 140
Hodgkin Lymphoma - Dormant Projects 199
Hodgkin Lymphoma - Discontinued Products 200
Hodgkin Lymphoma - Product Development Milestones 201
Featured News & Press Releases 201
May 14, 2014: Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Receives U.S. FDA Breakthrough Therapy Designation for Hodgkin Lymphoma 201
Apr 10, 2014: Affimed Highlights Further Data on AFM13, a Bispecific CD30/CD16A TandAb in Development to Treat Hodgkin Lymphoma, at the 2014 AACR Annual Meeting 201
Apr 07, 2014: TG Therapeutics Announces Preclinical Poster Presentations for TGR-1202 at AACR 2014 202
Feb 27, 2014: Seattle Genetics Highlights ADCETRIS Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings 203
Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 204
Dec 05, 2013: TG Therapeutics Announces Poster Presentations for TGR-1202 at the Upcoming 55th American Society of Hematology Meeting 205
Oct 11, 2013: Seattle Genetics Highlights ADCETRIS (Brentuximab Vedotin) Clinical Data in the Frontline Setting at the International Symposium on Hodgkin Lymphoma 206
Sep 16, 2013: Affimed Therapeutics and The Leukemia & Lymphoma Society Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients 208
Jun 24, 2013: Affimed Reports Phase I Clinical Data For Its Immunotherapy AFM13 In Relapsing/Refractory Hodgkin Lymphoma Patients 209
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML 210
Appendix 213
Methodology 213
Coverage 213
Secondary Research 213
Primary Research 213
Expert Panel Validation 213
Contact Us 214
Disclaimer 214

List of Tables
Number of Products under Development for Hodgkin Lymphoma, H2 2014 12
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Late Stage Development, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Development, H2 2014 21
Comparative Analysis by Unknown Stage Development, H2 2014 22
Products under Development by Companies, H2 2014 23
Products under Investigation by Universities/Institutes, H2 2014 24
Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 25
Hodgkin Lymphoma - Pipeline by Johnson & Johnson., H2 2014 26
Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2014 27
Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2014 28
Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H2 2014 29
Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 30
Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2014 31
Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 32
Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2014 33
Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2014 34
Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2014 35
Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2014 36
Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 37
Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2014 38
Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 39
Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H2 2014 40
Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2014 41
Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2014 42
Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014 43
Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2014 44
Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H2 2014 45
Hodgkin Lymphoma - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 46
Assessment by Monotherapy Products, H2 2014 47
Number of Products by Stage and Target, H2 2014 50
Number of Products by Stage and Mechanism of Action, H2 2014 54
Number of Products by Stage and Route of Administration, H2 2014 57
Number of Products by Stage and Molecule Type, H2 2014 60
Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 140
Hodgkin Lymphoma - Dormant Projects, H2 2014 199
Hodgkin Lymphoma - Discontinued Products, H2 2014 200

List of Figures
Number of Products under Development for Hodgkin Lymphoma, H2 2014 12
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Late Stage Development, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Products, H2 2014 21
Assessment by Monotherapy Products, H2 2014 47
Number of Products by Top 10 Target, H2 2014 48
Number of Products by Stage and Top 10 Target, H2 2014 49
Number of Products by Top 10 Mechanism of Action, H2 2014 52
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 53
Number of Products by Top 10 Route of Administration, H2 2014 56
Number of Products by Stage and Top 10 Route of Administration, H2 2014 57
Number of Products by Top 10 Molecule Type, H2 2014 58
Number of Products by Stage and Top 10 Molecule Type, H2 2014 59

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top